姜黄素壳聚糖微球的制备及其在体内外释放度的研究

目的:研究响应面法优化姜黄素壳聚糖微球制备的工艺参数,提高姜黄素的溶出度.方法:采用离子交联法制备姜黄素缓释微球,以微球的载药量和包封率为考察指标,采用星点设计考察配制壳聚糖的醋酸浓度、药物载体的比例以及交联剂浓度对微球制备工艺的影响,对结果进行二次多项式拟合,并根据最佳数学模型进行预测.结果:姜黄素壳聚糖微球最优制备工艺参数为:醋酸的浓度为1％,载体药物比例为0.83,交联剂的浓度为0.15％,载药量和包封率的预测值和理论值偏差分别为0.47％和3.2％.结论:响应面法优化姜黄素壳聚糖微球制剂处方具有很好的预测性,体内外药物释放度研究表明,最优条件下制备的微球可以在提高姜黄素溶出度的前提下缓慢释放达12h.     

壳聚糖-海藻酸钠包裹Hp全菌蛋白微球剂的研制及其表征分析

以壳聚糖、海藻酸钠为主要合成材料包裹幽门螺杆菌全菌超声蛋白抗原 ,制备新型Hp疫苗制剂。采用一定工艺 ,将海藻酸钠、壳聚糖以及Hp超声全菌抗原制备成W /O/W微球。通过扫描电镜、粒径分布仪等设备检测微球粒径大小 ;微球溶出度仪、Lowry法检测蛋白含量、高压液相色谱等检测微球的蛋白的包封率以及释放速率 ;12 5I标记后口服观测微球的定向靶向作用等。所制备微球形态规则 ,粒径均在 10 μm以内 ;包封率达到 4 1%左右 ;整个包封过程对蛋白没有任何降解作用 ;微球呈缓 快 缓释药模式 ,药物缓释时间可长达 72h ;微球在肠PP结分布明显高…     

均匀设计法优化硝酸咪康唑微球的制备工艺

目的：以均匀设计法筛选优化硝酸咪康唑苹果酸化壳聚糖微球的制备工艺,提供可控性及预测性,并对微球稳定性和药物释放规律进行研究。方法：采用乳化交联法制备微球。采用U5（53）试验表进行试验,分别考察各处方的制备的微球的形态和粒径、载药量和包封率。利用SPSS软件进行多元线性回归拟合,得到方程及优化工艺条件。结果：优化方程的预测值与实验值之间有较好的吻合性。制备出的微球可以在室温（25℃）条件下保存;微球的药物释放动力学可用一级动力学方程来描述。结论：本实验通过均匀设计法优化硝酸咪康唑微球的制备工艺预测性好且制备的微球性能良好。     

萘普生缓释微球制备工艺及性能研究

本文利用壳聚糖和海藻酸钠通过复凝聚法将萘普生制成微球,研究成球的最佳制备工艺条件及载药微球性能,制备了可生物相容,自然降解无毒的载药微球。实验中,以微球的药物包封率为制备工艺优化指标,通过正交实验得出微球的最佳制备工艺条件为:壳聚糖浓度∶海藻酸钠浓度为1:1,pH值为4.0,搅拌速度为300rpm,反应温度为35℃。以最佳制备工艺条件制备的含药微球,重现性好,工艺稳定,同时体外溶出实验表明,该微球具有较好的缓释作用。     

壳聚糖装载猪胸腺肽微球给药

目的：以猪胸腺肽为芯材、壳聚糖为壁材,采用乳化交联结合单凝聚法制备猪胸腺肽壳聚糖口服微球。方法：以壁材浓度、交联剂含量、油水比值、芯材壁材比值为四因素设计正交实验,确定微球最佳制备条件,并对其体外释放及稳定性进行研究。结果：制备微球最优化条件为壳聚糖浓度1％、25％戊二醛含量7％、油水比值2：1、壳聚糖与胸腺肽比值1：1;微球在pH1．5的HC1溶液中2h释放30％,在pH6．8及7．4的PBS缓冲液中最终释放度约80％,并在24h达到释放终点;微球30rain突释率约为10％,1h释放率约为20％,其后缓慢而持续地释放;猪胸腺肽壳聚糖微球在0℃保存8个月时微球外观及形态没有差异,药物剩余率约为91．8％。结论：采用乳化交联结合单凝聚法制备的猪胸腺肽壳聚糖口服微球为缓释给药系统的临床应用奠定了理论基础,具有重要的实际应用价值和社会意义。     

酮戊二酸改性壳聚糖微球的制备及其对来氟米特的缓释

采用反相悬浮法制备交联壳聚糖微球,再与α-酮戊二酸反应生成Schiff碱,以NaBH_4还原制得改性壳聚糖微球.用FT-IR,SEM和XRD进行表征.并以来氟米特(LEF)为模型药物,考察了其缓释效果.结果显示:微球对药物的最大包封率为94%,载药量为62%,在缓释初期2 h内微球平均释放药量的16%,后期则呈现缓慢释放的趋势.本论文采用的微粒的药物承载量和释放速度既保证了药物的药效又降低了药物释放速率过快引起的对人体的不良反应.     

可控性释放NGF的京尼平- 壳聚糖微球的研究

目的:在体外研究京尼平-壳聚糖微球可控性释放具有生物活性的神经生长因子的可行性。方法:采用"乳化-化学交联"技术制备包埋神经生长因子的京尼平-壳聚糖微球,京尼平为化学交联剂;应用扫描电镜、粒径分布、体外缓释动力学及细胞生物活性分别对微球的性能进行研究。结果:京尼平-壳聚糖微球表面光滑,平均粒径在5.1~50.5μm之间;京尼平的浓度可影响微球在体外释放神经生长因子的速度,经高浓度京尼平交联的微球能减缓并持续释放神经生长因子;此外,从京尼平-壳聚糖微球释放的神经生长因子可维持PC12细胞的生物活性,提高NGF生物利用率。结论:京尼平-壳聚糖微球能有效缓释具有生物活性的NGF超过14天,为神经退行性疾病的治疗提供一种治疗策略。     

载阿霉素PLGA纳米微球的制备及性质研究

目的:制备新型癌症化疗制剂载阿霉素(Adriamycin)、聚乳酸-羟基乙酸共聚物(PLGA)纳米微球(ADM-PLGA-NP),研究其性质及体外释药特点。方法:以聚乳酸-羟基乙酸共聚物为包封材料,阿霉素为模型药物,采用复乳蒸发法制备ADM-PLGA-NP,扫描电镜观察微球形态,激光粒度分析仪检测粒径分布,紫外分光光度法计算载药率及包封率,体外药物释放实验考察微球对ADM的缓释作用。结果:ADM-PLGA-NP外观呈球形,平均粒径约(237±12.7)nm,载药量及包封率分别为(6.42±1.67)%和(53.82±8.34)%,药物在体外缓慢释放,5 d累积释放量达85%。结论:通过复乳蒸发法制备的ADM-PLGA-NP性质稳定,具有药物缓释性,有望成为一种新型的药物化疗载体。     

大肠杆菌微球包封效率及稳定性的研究

多聚物制备而成的微球是一种具有佐剂效应的疫苗控释系统,在疫苗研制中得到广泛应用.为改进大肠杆菌疫苗的制备质量,本文以天然高分子聚合物海藻酸钠和壳聚糖为材料,应用了三种不同制备微球的方法来制备大肠杆菌微球,观察微球的形态、粒径和稳定性,并测算其对大肠杆菌的包封率.结果表明,采用乳化-内部凝胶化法制备的大肠杆菌海藻酸钙-壳聚糖微球,圆整规则,粒径较小,包封率达到≈93.1％,具有良好的控释性能和稳定性,适于低温保存.     

高分子药物缓释用壳聚糖微球的制备

本文采用了先交联制备可溶胀的壳聚糖载体微球,后将模型高分子药物以被动吸咐方式担载在溶胀的微球内的两步法,制备缓释高分子药物微球,避免了高分子药物接触有机试剂引起的活性损失。     

Synthesis and characterization of semi-interpenetrating polymer network microspheres of acrylamide grafted dextran and chitosan for controlled release of acyclovir

Semi-interpenetrating polymer network (IPN) microspheres of acrylamide grafted on dextran (AAm-g-Dex) and chitosan (CS) were prepared by emulsion-crosslinking method using glutaraldehyde (GA) as a crosslinker. The grafting efficiency was found to be 94%. Acyclovir, an antiviral drug with limited water solubility, was successfully encapsulated into IPN microspheres by varying the ratio of AAm-g-Dex and CS, % drug loading and amount of GA. Microspheres were characterized by FT-IR spectroscopy to assess the formation of IPN structure and to confirm the absence of chemical interactions between drug, polymer and crosslinking agent. Particle size was measured using laser light scattering technique. Microspheres with average particle sizes in the range of 265–388 μm were obtained. Differential scanning calorimetry (DSC) and X-ray diffraction (X-RD) studies were performed to understand the crystalline nature of drug after encapsulation into IPN microspheres. Acyclovir encapsulation of up to 79.6% was achieved as measured by UV spectroscopy. Both equilibrium and dynamic swelling studies were performed in 0.1 N HCl. Diffusion coefficients (D) and diffusional exponents (n) for water transport were determined using an empirical equation. In vitro release studies indicated the dependence of drug release rates on both the extent of crosslinking and amount of AAm-g-Dex used in preparing microspheres; the slow release was extended up to 12 h. The release rates were fitted to an empirical equation to compute the diffusional exponent (n), which indicated non-Fickian trend for the release of acyclovir.     

Novel interpenetrating polymer network microspheres of chitosan and methylcellulose for controlled release of theophylline

Interpenetrating polymer network (IPN) microspheres of chitosan (CS) and methylcellulose (MC) were prepared by emulsion-crosslinking in the presence of glutaraldehyde (GA) as a crosslinker. Theophylline (THP), an antiasthmatic drug was encapsulated into IPN microspheres under varying ratios of MC and CS, % drug loading and amount of GA added. IPNs have shown better mechanical properties than pure CS. Cross-link density of the matrices was significantly affected by the amount of GA and MC. Microspheres were characterized by Fourier transform infrared (FTIR) spectroscopy to assess the formation of IPN structure and to confirm the absence of chemical interactions between drug, polymer and crosslinking agent. Particle size was measured by laser light scattering technique. Microspheres with the average particle sizes ranging from 119 to 318 μm were produced. Differential scanning calorimetry (DSC) and X-ray diffraction (X-RD) studies were performed to understand the crystalline nature of drug after encapsulation into IPN microspheres. Theophylline encapsulation of up to 82% was achieved as measured by UV spectrometer. Equilibrium swelling was performed in distilled water. In vitro release studies were performed in both 0.1 N HCl and pH 7.4 buffer solutions. These data indicated a dependence of drug release on the extent of crosslinking and amount of MC added during the preparation of microspheres. The release was extended up to 12 h and release rates were fitted to an empirical equation to compute the diffusional parameters, which indicated a slight deviation from the Fickian trend for the release of theophylline.     

Poly(3-hydroxybutyrate)/chitosan/ketoprofen or piroxicam composite microparticles: Preparation and controlled drug release evaluation

Poly(3-hydroxybutyrate)/chitosan/piroxicam or ketoprofen composite microparticles were prepared by the solid-in-water-in-oil emulsion-solvent evaporation technique with the aim of reducing the burst effect and controlling the drug release. Reservoir-type microparticles, composed of poly(3-hydroxybutyrate) microspheres embedded in a chitosan matrix were prepared. The size and morphological characteristics of the composite microparticles were evaluated in relation to the chitosan concentration and cross-linking with glutaraldehyde. Reservoir-type composite microparticles were obtained using 2.0% and 3.0% w/v chitosan solutions. A significant reduction in the burst effect and prolonged drug release were observed, particularly when higher chitosan and glutaraldehyde concentrations were used.     

Gadolinium diethylenetriaminopentaacetic acid-loaded chitosan microspheres for gadolinium neutron-capture therapy

In order to provide a suitable device that would contain water-soluble drugs, highly water-soluble gadolinium diethylenetriaminopentaacetic acid-loaded chitosan microspheres (CMS-Gd-DTPA) were prepared by the emulsion method using glutaraldehyde as a cross-linker and Span 80 as a surfactant for gadolinium neutron-capture therapy of cancer. The gadolinium content and the mass median diameter of CMS-Gd-DTPA were estimated. The size and morphology of the CMS-Gd-DTPA were strongly influenced by the initial applied weight ratio of Gd-DTPA:chitosan. FTIR spectra showed that the electrostatic interaction between chitosan and Gd-DTPA accelerated the formation of gadolinium-enriched chitosan microspheres. Sufficient amounts of glutaraldehyde and Span 80 were necessary for producing discrete CMS-Gd-DTPA. The CMS-Gd-DTPA having a mass median diameter 11.7microm and 11.6% of gadolinium could be used in Gd-NCT following intratumoral injection.     

Ethylcellulose-Based Matrix-Type Microspheres: Influence of Plasticizer RATIO as Pore-Forming Agent

In this study, ethylcellulose (EC)-based microsphere formulations were prepared without and with triethyl citrate (TEC) content of 10% and 30% by water-in-oil emulsion-solvent evaporation technique. Diltiazem hydrochloride (DH) was chosen as a hydrophilic model drug and used at different drug/polymer ratios in the microspheres. The aim of the work was to evaluate the influence of plasticizer ratio on the drug release rate and physicochemical characteristics of EC-based matrix-type microspheres. The resulting microspheres were evaluated for encapsulation efficiency, particle size and size distribution, surface morphology, total pore volume, thermal characteristics, drug release rates, and release mechanism. Results indicated that the physicochemical properties of microspheres were strongly affected by the drug/polymer ratio investigated and the concentration of TEC used in the production technique. The surface morphology and pore volume of microspheres significantly varied based on the plasticizer content in the formulation. DH release rate from EC-based matrix-type microspheres can be controlled by varying the DH to polymer and plasticizer ratios. Glass transition temperature values tended to decrease in conjunction with increasing amounts of TEC. Consequently, the various characteristics of the EC microspheres could be modified based on the plasticized ratio of TEC.     

壳聚糖/有机累托石微球的合成及表征

目的:以牛血清白蛋白(BSA)作为模型药物,制备壳聚糖/有机累托石复合物微球,建立一种安全有效的药物控释传递系统。方法:壳聚糖(CS)/有机累托石(OREC)和海藻酸钠,按照不同的混合比例交联,在Ca2+水溶液中包裹BSA而形成壳核结构的微球。采用傅立叶红外光谱(FTIR)、动态光散射(DLS)、原子力显微镜(AFM)、X-衍射(XRD)、扫描电镜(SEM)和透射电镜(TEM)观察研究微球的形态、CS和OREC的插层结构、BSA的包封率和控释效果。结果:口光学显微镜和扫描电镜观察显示,形成了壳核结构的微球。傅里叶变换光谱和X-射线能量分散显示,OREC存在于微球中。小角X-射线衍射证实,CS链成功的插入OREC插层中。BSA的包封率和控释检测结果显示,与纯的CS/ALG形成的微球相比较,CO复合物所形成的微球药物释放率明显提高。结论:OREC-HTCC纳米粒子是良好的蛋白药物载体,具有包封率高、缓释效果好等优点,为CS-OREC作为潜在的药物给药系统的进一步应用提供科学依据。     

用壳聚糖纳米磁性微球纯化血红细胞超氧化物歧化酶

本研究旨在用壳聚糖-聚丙烯酸纳米磁性微球纯化血红细胞超氧化物歧化酶。采用了接枝共聚法,以K2S2O8为引发剂,使壳聚糖(CTS)与聚丙烯酸(PAA)进行自由接枝共聚合成含有两性基团(-NH3,-COOH)的壳聚糖-聚丙烯酸纳米微球。化学共沉淀法制备Fe3O4磁流体,以戊二醛为交联剂,制备壳聚糖-聚丙烯酸纳米磁性微球。用傅里叶变换红外光谱仪对磁性微球结构进行检测。JEM-4000EX电镜技术对微球粒径,形貌进行表征。SOD试剂盒测定各步骤Cu-ZnSOD酶活性。结果表明,壳聚糖-聚丙烯酸纳米磁性微球有较好的粒径分布、磁响应性及蛋白吸附特性。纯化后酶比活性达6 727 U/mg,产品得率21.1%,活性回收85.7%。壳聚糖-聚丙烯酸纳米磁性微球经血液纯化血红细胞SOD具有可再生性、易操作性,其纯化效果取决于金属Cu2+的螯合程度。     

Preparation and characterization of glutaraldehyde cross-linked O-carboxymethylchitosan microspheres for controlled delivery of pazufloxacin mesilate

O-carboxymethylchitosan (OCMC) microspheres containing an antibiotic drug pazufloxacin mesilate (PM) have been successfully prepared by emulsion cross-linking using glutaraldehyde (GA). Various manufacturing parameters, including amount of cross-linking agent and OCMC:PM ratios were altered to optimize process variables during the microspheres production. The structure and morphology were characterized by Fourier transform infrared (FT-IR), wide-angle X-ray diffraction (WXRD) and scanning electron microscopy (SEM). The swelling and releasing behaviors of the microspheres at pH 1.2 and 7.4 media were investigated. The results revealed that the microspheres had a spherical, rough morphology and with a narrow size distribution. The degree of swelling of microspheres at pH 7.4 media was higher than that at pH 1.2 media. The microspheres proved to be successful in prolonging drug release. The release of PM was found to depend upon the extent of matrix cross-linking and drug loading. The release profiles of PM from OCMC microspheres were found to be biphasic with a burst release followed by a gradual release phase, and followed the Higuchi matrix model.     

Two-stage optimization process for formulation of chitosan microspheres

The objective of the present study was to optimize the concentration of a chitosan solution, stirring speed, and concentration of drugs having different aqueous solubility for the formulation of chitosan microspheres. Chitosan microspheres (unloaded and drug loaded) were prepared by the chemical denaturation method and were subjected to measurement of morphology, mean particle size, particle size distribution, percentage drug entrapment (PDE), drug loading, and drug release (in vitro). Morphology of the microspheres was dependent on the level of independent process parameters. While mean particle size of unloaded microspheres was found to undergo significant change with each increase in concentration of chitosan solution, the stirring rate was found to have a significant effect only at the lower level (ie, 2000 to 3000 rpm). Of importance, spherical unloaded microspheres were also obtained with a chitosan solution of concentration less than 1 mg/mL. Segregated unloaded microspheres with particle size in the range of 7 to 15 microm and mean particle size of 12.68 microm were obtained in the batch prepared by using a chitosan solution of 2 mg/mL concentration and stirring speed of 3000 rpm. The highest drug load ( microg drug/mg microspheres) was 50.63 and 13.84 for microspheres containing 5-fluorouracil and methotrexate, respectively. While the release of 5-fluorouracil followed Higuchi's square-root model, methotrexate released more slowly with a combination of first-order kinetics and Higuchi's square-root model. The formation of chitosan microspheres is helped by the use of differential stirring. While an increase in the concentration of water-soluble drug may help to increase PDE and drug load over a large concentration range, the effect is limited in case of water-insoluble drugs.     

Synthesis and characterization of pH-sensitive hydrogel composed of carboxymethyl chitosan for colon targeted delivery of ornidazole

In the present study, carboxymethyl chitosan was prepared from chitosan, crosslinked with glutaraldehyde and evaluated in vitro as a potential carrier for colon targeted drug delivery of ornidazole. Ornidazole was incorporated at the time of crosslinking of carboxymethyl chitosan. The chitosan was evaluated for its degree of deacetylation (DD) and average molecular weight; which were found to be 84.6% and 3.5×10(4) Da, respectively. The degree of substitution on prepared carboxymethyl chitosan was found to be 0.68. All hydrogel formulations showed more than 85% and 74% yield and drug loading, respectively. The swelling behaviour of prepared hydrogels checked in different pH values, 1.2, 6.8 and 7.4, indicated pH responsive swelling characteristic with very less swelling at pH 1.2 and quick swelling at pH 6.8 followed by linear swelling at pH 7.4 with slight increase. In vitro release profile was carried out at the same conditions as in swelling and drug release was found to be dependant on swelling of hydrogels and showed biphasic release pattern with non-fickian diffusion kinetics at higher pH. The carboxymethylation of chitosan, entrapment of drug and its interaction in prepared hydrogels were checked by FTIR, (1)H NMR, DSC and p-XRD studies, which confirmed formation of carboxymethyl chitosan from chitosan and absence of any significant chemical change in ornidazole after being entrapped in crosslinked hydrogel formulations. The surface morphology of formulation S6 checked before and after dissolution, revealed open channel like pores formation after dissolution.